A new partnership between the Alzheimer’s Disease Data Initiative (ADDI) and Vivli expands access to critical clinical trial data from leading pharmaceutical companies.
Today, the Alzheimer’s Disease Data Initiative (ADDI) and Vivli – two leading health data organizations – announced a new partnership. It is aimed at expanding access and interoperability of data from completed clinical trials related to finding new treatments and cures for Alzheimer’s disease and related dementias. The new partnership enables researchers worldwide to request datasets from leading global pharmaceutical companies Eli Lilly (Lilly) and GlaxoSmithKline (GSK) through the Vivli platform and analyze it in ADDI’s data sharing platform – the AD Workbench. This partnership will provide researchers with high quality data from a range of sources that can be interrogated and analyzed all together for the first time. The end goal is that these novel analyses may lead to new insights into this devastating disease.
“There is still so much we need to learn about Alzheimer’s disease and related dementias, and widely accessible, high-quality data from clinical trials will be a critical part of the solution” said Tetsu Maruyama, Executive Director of ADDI. “Through this partnership with Vivli, we’re excited to make clinical trial data available in the AD Workbench. This allows researchers around the globe and across disciplines to use these data to generate and test important new hypotheses. We look forward to growing this partnership in the months ahead.”
“Lilly and GSK are making an important contribution to Alzheimer’s and dementia by allowing their data to be combined with data on ADDI,” said Rebecca Li, Vivli Executive Director. “We are optimistic that the ability to combine these datasets with those on an Alzheimer’s and dementia-focused platform will hopefully move us closer to real-world insights for these devastating diseases.”
The AD Workbench is a global platform that focuses on collaboration and data sharing – to accelerate discoveries and innovations in Alzheimer’s disease and related dementias. Vivli is the world’s largest clinical research data sharing platform and shares data, including Alzheimer’s disease, from more than 6,000 completed trials. Both ADDI and Vivli provide a secure way for researchers from around the globe to request, access and analyze data.
“Harnessing more than three decades of research into Alzheimer’s disease, we have made significant progress in understanding the disease pathology of Alzheimer’s and pioneering diagnostics and therapeutics to potentially modify disease progression,” said Anne E. White, senior vice president and president, Lilly Neuroscience, Eli Lilly and Company. “We are excited to partner with ADDI and Vivli to enhance Alzheimer’s research and hope that this initiative will further understanding and action to help people with this disease.”
To learn more about ADDI and the AD Workbench, please visit www.alzheimersdata.org.
To learn more about Vivli, please visit www.vivli.org.
Alzheimer’s Disease Data Initiative (ADDI), a 501 (c)(3) medical research organization (MRO) in partnership with the University of Washington, is dedicated to advancing scientific breakthroughs in the treatment of Alzheimer’s disease and related dementias. ADDI aims to increase interoperability of existing data platforms globally, increase sharing of dementia-related data from academic and industry sources, and empower scientists to find, search, combine, and analyze data that could lead to new discoveries in dementia research. ADDI also aims to enhance or fill gaps in datasets, including enabling the generation of more demographically representative datasets. LinkedIn: AlzheimersData Twitter: AlzData. For further information, contact Shirley Prasad, email: email@example.com.
Vivli is a non-profit organization working to advance human health through the insights and discoveries gained by sharing and analyzing data. It is home to an independent global data-sharing and analytics platform which serves all elements of the international research community. The platform includes a data repository, in-depth search engine and cloud-based analytics, and harmonizes governance, policy and processes to make sharing data easier. Vivli acts as a neutral broker between data contributor and data user and the wider data sharing community. For more information, visit www.vivli.org and follow us on Twitter @VivliCenter. For further information, contact; Julie Wood, Director of Strategy and Operations, email: firstname.lastname@example.org tel: 0015735143305